Patents by Inventor Josef Krieglstein

Josef Krieglstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of S-Clenbuterol
    Publication number: 20100240764
    Abstract: The use of S-Clenbuterol for restoring and/or maintaining the function of partially or completely damaged/degenerated cells in the central nervous system and/or other nerve cells is claimed. The use of S-Clenbuterol leads to activation of astrocytes and initiation of endogenous processes of neuroprotection, it thus being possible for the damage or destruction of nerve cells to be reduced and, in some cases, even prevented.
    Type: Application
    Filed: February 1, 2006
    Publication date: September 23, 2010
    Applicant: EUCRO EUROPEAN CONTRACT RESEARCH GMBH & CO. KG
    Inventors: Wolfgang Greb, Josef Krieglstein, Carsten Culmsee
  • Substrate for PP2C
    Patent number: 6933127
    Abstract: The invention relates to a combination of a protein phosphatase type 2C as an enzyme and a phospho-BAD as substrate. The protein BAD is dephosphorylated in position Ser155. Furthermore, the combination is used in an in vitro screening for ligands which modulate protein phosphatase type 2C, comprising the steps: incubating the protein phosphatase type 2C in combination with the substrate phospho-BAD and the ligand of the assay and detecting the decrease in phospho-BAD and/or the increase in phosphate and/or BAD. Therefore, new drugs for the treatment apoptosis may be found.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: August 23, 2005
    Assignee: EUCRO European Contract Research GmbH & Co. KG
    Inventors: Josef Krieglstein, Susanne Klumpp
  • Use of $g(b)-adrenoceptor agonists for the treatment of neurodegenerative diseases
    Publication number: 20040248984
    Abstract: The use of &bgr;-adrenoceptor agonists for restoring and/or maintaining the function of partially or completely damaged/degenerated cells in the central nervous system and/or other nerve cells is claimed. The use of &bgr;2-adrenoceptor agonists leads to activation of astrocytes and initiation of endogenous processes of neuroprotection, it thus being possible for the damage or destruction of nerve cells to be reduced and, in some cases, even prevented.
    Type: Application
    Filed: August 3, 2004
    Publication date: December 9, 2004
    Inventors: Josef Krieglstein, Carsten Culmsee, Vera Junker, Helmut Blum, Wolfgang Greb
  • Substrate for PP2C
    Publication number: 20030044875
    Abstract: The invention relates to a combination of a protein phosphatase type 2C as an enzyme and a phospho-BAD as substrate. The protein BAD is dephosphorylated in position Ser155. Furthermore, the combination is used in an in vitro screening for ligands which modulate protein phosphatase type 2C, comprising the steps: incubating the protein phosphatase type 2C in combination with the substrate phospho-BAD and the ligand of the assay and detecting the decrease in phospho-BAD and/or the increase in phosphate and/or BAD. Therefore, new drugs for the treatment apoptosis may be found.
    Type: Application
    Filed: July 3, 2002
    Publication date: March 6, 2003
    Applicant: Schering AG
    Inventors: Josef Krieglstein, Susanne Klumpp